Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2012

View Archived Issues

Ono Pharmaceutical updates progress of second quarter of fiscal 2012

Pevion Biotech launches new immune enhancement platform

Successful results reported for phase IIb trial of bremelanotide

XenoPort reacquires rights to Horizant

SGX-203 granted FDA fast track designation

Novel RNAi therapeutic significantly reduces triglycerides and LDL

Mutations in CYP26C1 associated with FFDD type IV

Kowa describes preclinical testing of novel cholesteryl ester transfer protein inhibitor

Researchers at Compugen present new fusion proteins

VS-5584 treatment inhibits cancer stem cells in vitro and in vivo

U.S. team prepares novel MAbs for cancer

New antibacterial agents synthesized by Canadian researchers

Novel BACE1/BACE2 inhibitors divulged by Merck & Co.

Scientists at Merck & Co. report novel MR antagonists

Biotron begins phase II BIT-225 trial in patients with HIV and HCV

Biota provides update on merger

Daiichi Sankyo submits supplemental NDA for Topotecin in Japan

FDA advisory committee votes on insulin degludec NDAs

Novel biomarker for the diagnosis of ACS presented by Japanese group

Myrexis board approves plan of complete liquidation and dissolution

Promising phase I results reported for subcutaneous MOR-103

AstraZeneca reports topline results from pivotal trials of naloxegol

Researchers in Australia present new agents for glaucoma

Pharma Eight presents novel agents for Alzheimer's disease

Pivotal HEAT Study of ThermoDox in primary liver cancer reaches target for unblinding

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...